TrialJAMA2017

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Pasi A Jänne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.